We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

157 hedge funds and large institutions have $1.59B invested in Arcus Biosciences in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 55 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $23.4M | Put options by funds: $11.1M

79% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 19

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

11% more funds holding

Funds holding: 142 → 157 (+15)

1.11% less ownership

Funds ownership: 72.35% → 71.25% (-1.1%)

20% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 55

23% less capital invested

Capital invested by funds: $2.06B → $1.59B (-$468M)

Holders
157
Holders Change
+15
Holders Change %
+10.56%
% of All Funds
2.48%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.13%
New
34
Increased
44
Reduced
55
Closed
19
Calls
$23.4M
Puts
$11.1M
Net Calls
+$12.3M
Net Calls Change
+$15.5M

Top Buyers

1
AllianceBernstein
AllianceBernstein
Tennessee
+$34.4M
2
APM
Avidity Partners Management
Texas
+$30.6M
3
BI
BVF Inc
California
+$18.9M
4
State Street
State Street
Massachusetts
+$18.7M
5
PA
Perceptive Advisors
New York
+$13.6M

Top Sellers

1
EC
EcoR1 Capital
California
-$75.7M
2
WP
Woodline Partners
California
-$48.4M
3
Morgan Stanley
Morgan Stanley
New York
-$39.7M
4
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$15M
5
Franklin Resources
Franklin Resources
California
-$14.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
26
UBS AM
Illinois
$9.9M +$2.43M +72,627 +30%
Invesco
27
Invesco
Georgia
$9.26M +$3.18M +94,844 +48%
GGHC
28
Gilder Gagnon Howe & Co
New York
$9.19M -$46.5K -1,388 -0.5%
N
29
Nuveen
North Carolina
$8.93M -$41K -1,224 -0.5%
WP
30
Woodline Partners
California
$8.25M -$48.4M -1,445,006 -85%
Morgan Stanley
31
Morgan Stanley
New York
$7.91M -$39.7M -1,183,774 -83%
Goldman Sachs
32
Goldman Sachs
New York
$7.78M +$4.49M +133,979 +119%
GIM
33
Granahan Investment Management
Massachusetts
$7.13M +$2.97M +88,663 +65%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$6.71M -$1.8M -53,800 -20%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$6.65M -$979K -29,229 -12%
Deutsche Bank
36
Deutsche Bank
Germany
$6.35M -$79K -2,357 -1%
TCM
37
Tang Capital Management
California
$6.31M +$6.7M +200,000 New
UBS Group
38
UBS Group
Switzerland
$6.12M +$6.3M +188,069 +3,237%
BCPEMI
39
Bain Capital Public Equity Management II
Massachusetts
$5.92M -$7.88M -235,193 -56%
LCM
40
Laurion Capital Management
New York
$5.72M +$6.07M +181,244 New
SC
41
Sessa Capital
New York
$5.71M +$6.06M +181,000 New
Marshall Wace
42
Marshall Wace
United Kingdom
$5.64M +$5.98M +178,565 New
PHP
43
Parkman Healthcare Partners
Connecticut
$5.28M +$1.68M +50,222 +43%
PAM
44
Panagora Asset Management
Massachusetts
$5.18M +$291K +8,684 +6%
Rafferty Asset Management
45
Rafferty Asset Management
New York
$5.1M +$1.18M +35,236 +28%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$4.88M -$4.06M -121,200 -44%
DCM
47
DAFNA Capital Management
California
$4.58M +$939K +28,017 +24%
Bank of America
48
Bank of America
North Carolina
$4.34M +$1.34M +39,989 +41%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$4.25M +$2.62M +78,124 +138%
Axa
50
Axa
France
$4.25M – – –
1
2
3 4 5

RCUS Hedge Fund Activity: Q1 2022 in Review

157 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2022, worth a combined $1.59B — down 23% from $2.06B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new RCUS positions and 19 closed out — a net gain of 15 holders — while 44 added to existing stakes and 55 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $34.4M. The largest seller was EcoR1 Capital, cutting an estimated $75.7M.

  • 157 institutional investors held Arcus Biosciences (RCUS) as of Q1 2022, up from 142 in Q4 2021.
  • Funds reported $1.59B of Arcus Biosciences stock for Q1 2022, down 23% quarter-over-quarter.
  • 34 funds opened new Arcus Biosciences positions in Q1 2022 and 19 closed out, a net change of +15 holders.
  • The largest Arcus Biosciences buyer in Q1 2022 was AllianceBernstein, an estimated $34.4M added.
  • The largest Arcus Biosciences seller in Q1 2022 was EcoR1 Capital, an estimated $75.7M sold.

Based on aggregated 13F filings for Q1 2022.